ONCOSYNERGY - Key Persons
Job Titles:
- VP of Corporate / Clinical Operations
Ms. Picon has extensive experience working hand in hand with C-suite and expertise in integrating efficient processes to position company operations for venture success. She takes pride in her keen process-oriented solutions and proactively problem-solving. Ms. Picon's leadership has empowered our virtual, capital efficient business model. She also plays an active role in coaching team members, instilling key corporate values and concepts critical to OncoSynergy's success. Ms. Picon's background includes pre-medical studies and supporting top doctors and managing partners at private medical offices, gaining her valuable patient care experience. Frustrated with inefficiencies negatively affecting workflow and patient care, she implemented streamline operations which reduced costs and recovered money left on the table. Self-driven and passionate about making an impact in areas of unmet needs, Ms. Picon joined OncoSynergy's mission in 2019 and has quickly become a rising star within our team.
Dr. Damsky is a pioneer in the study of integrins beginning her studies in the laboratory of Clayton Buck at the Wistar Institute. Later, at UCSF, she developed some of the first monoclonal antibodies against human integrin receptors. She is Professor Emeritus and former Assoc. Dean of Academic Affairs, UCSF.
Job Titles:
- Clinical Research Scientist
As Clinical Research Scientist, Dr. Rolle-McFarland oversees OncoSynergy's Chemistry, Manufacturing, and Control (CMC) Program, ensuring a cohesive collaboration among our CROs and expert CMC consultant. Prior to OncoSynergy, she completed a 1-year postdoc in Cancer Epidemiology at Moffitt Cancer Center, our Phase I clinical trial site, making her a natural fit to our team and mission. Furthermore, she translated the foundation of her postdoc work into developing and launching OncoSynergy's tissue biomarker program, enabling collection of valuable data not usually captured in a Phase I trial. Dr. Rolle-McFarland received her BA in Chemistry from the College of Saint Benedict and a PhD and MPH from Purdue University, with a focus on Epidemiology and Public Health. She also authored several peer-reviewed publications, with her most recent contribution at OncoSynergy entitled "Endpoint in Ovarian Cancer Xenograph Model Predicted by Nighttime Motion Metrics," which has been published in Nature Lab Animal.
Job Titles:
- CEO
- Chief Medical Officer
- Founder
- Media Contact
Dr. Carbonell received her MD from St. Louis University (AOA, 1st in class) and trained in neurosurgery at the Cleveland Clinic. Prior to OncoSynergy, she gained valuable experience at MicroVention®, where she led pivotal trials at 35 clinical sites ultimately leading to FDA approval of 2 intracranial stents for treatment of brain aneurysms. At OncoSynergy, she translated decades of bench work into a manufactured product and successfully led FDA approval for our lead indication, glioblastoma. Leveraging her unique dual perspective as a clinician and patient, Dr. Carbonell leads OncoSynergy's Phase I trial at Moffitt Cancer Center. Dr. Carbonell's goal is to keep OncoSynergy at the forefront of translational science, medicine, and technology. She does so in part through her role as Principal Investigator on 2 active NIH grants, through active involvement in the Society of Neuro-oncology, and as a Senior Healthcare & Pharmaceutical Advisor to Ever Network (a Digital Health Company).
Mr. Wilson received his MBA in Accounting from the University of Colorado and a BS in Biological Science from Colorado State University. He has more than 30 years' experience in a variety of companies ranging from start-up to Fortune 500, public to private, and domestic to international. Prior to consulting, he was CFO at Micronics Computers (acquired by Diamond Multimedia) and Dyamics Isolation Systems (acquired by Berwind). Mr. Wilson's early finance career stems with Gates Corporation, the majority owner of LearJet.
Dr. Bizzari was the former Global Head of Oncology at Celgene. He is a 25-year veteran of the biopharma industry who led the clinical development and FDA approval of several cancer drugs including TAXOTERE®, ELOXATIN®, ABRAXANE® & IRINOTECAN®, as well as the glioblastoma therapies fotemustine and GLIADEL®.
Dr. Grady is a Board Certified neurosurgeon and the Charles Harrison Frazier Professor and Chairman of Neurosurgery at the University of Pennsylvania Perelman School of Medicine. He is the author of over 150 peer reviewed papers and 5 patents and a Co-Founder of the medical device company, Stereotaxis, Inc.
Dr. Aghi is a Board Certified neurosurgeon and Professor of Neurological Surgery at the UCSF. He received his dual degrees and trained in neurosurgery at Harvard Medical School. Dr. Aghi leads a NIH-funded laboratory focused on glioblastoma at the UCSF Brain Tumor Research Center.
Dr. Bissell is a pioneer studying the critical role of the tumor microenvironment in cancer progression and is a Distinguished Scientist at Lawrence Berkeley National Laboratory. She is the 2016 ASCB E.B. Wilson Medal awardee. Dr. Bissell gave an acclaimed TEDMed talk in 2012 highlighting her discoveries with over one million views.
Dr. Munster, herself a cancer survivor, is Professor of Medical Oncology at the UCSF. She is the Director of the UCSF Early Phase Clinical Trials Unit; Co-Leader of the UCSF Center for BRCA Research; and Leader of the UCSF Experimental Therapeutics Program.
Job Titles:
- Founding Executive Director of the Paul Allen Institute for Cell Science
Dr. Horwitz is the founding Executive Director of the Paul Allen Institute for Cell Science. He identified the the first fibronectin receptor leading to the discovery of the integrin family of adhesion and signaling receptors. He was a co-founder of and lead the Cell Migration Consortium supported by a decade of NIH funding.